At IMCAS 2026, Galderma will present findings supporting Sculptra’s regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7
Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane Shaype in shaping the chin, Restylane Lyft in improving jawline definition, Restylane Skinboosters in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme in correcting hollowing of the temples8-11
New data on the innovative neuromodulator Relfydess (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12
As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and educational capabilities at the congress

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator treatments at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The company will also showcase its leadership in community education through a number of events including two symposia, a live anatomy workshop, multiple masterclasses and meet-the-expert sessions, and a booth that will delve into the science behind its innovations.